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Abstract
Background: In clinical practice, it is difficult to monitor the repeating relapse in patients who have been suffering
from systemic lupus erythematosus (SLE). The underlying etiology remains largely unknown.
Methods: Aiming to understand the pathogenesis of SLE, a detailed study was conducted. Renal tubular cells–
derived iPSCs were successfully obtained from the urine of SLE patients and healthy controls. With the purpose to
identify simultaneous expression profiling of microRNA, mRNA and protein, Illumina HiSeq™ 2000 System and
iTRAQ-coupled 2D LC-MS/MS analysis were utilized in systemic lupus erythematosus-specific induced pluripotent
stem cells (SLE-iPSCs) and normal control-iPSCs (NC-iPSCs). The integration of multiple profiling datasets was
realized since it could facilitate the identification of non-seed miRNA targets, as well as differentially expressed
mRNAs and proteins.
Results: For this study, profiling datasets of 1099 differentially expressed mRNAs, 223 differentially expressed
microRNAs and 94 differentially expressed proteins were integrated. In order to investigate the influence of miRNA
on the processes of regulating mRNAs and proteins’ levels, potential targets of differentially expressed mRNAs and
proteins were predicted using miRanda, TargetScan and Pictar. Multiple profiling datasets were integrated to
facilitate the identification of miRNA targets, as well as differentially expressed mRNAs and proteins. Through gene
ontology (GO) analysis of differentially expressed mRNAs and proteins, biological processes that drive proliferation
were identified, such as mRNA processing and translation. Western blot and Q-PCR confirmed AK4 protein and
mRNA up-regulation. The findings also showed that TAGLN’s protein and mRNA level were down-regulated in
SLE-iPSCs, both miR-371a-5p and let-7a-5p in SLE-iPSC were down-regulated and verified using Q-PCR. The
up-regulation of AK4 involved in nucleotide biosynthesis suggested a general acceleration of anabolic metabolism
induced by down-regulated miR-371a-5p, which might contribute to SLE.
Conclusion: Based on high throughput analysis, integrated miRNA, mRNA, and protein expression data were
generated. Differentially expressed dates were also adopted in conjunction with in-silico tools to identify potential
candidates for SLE-iPSCs. Representative miRNA, mRNA and proteins were verified. It was also expected that the
knowledge gained from this study can be applied to assess the usefulness of pathogenesis and novel biomarker
candidates of SLE, which may develop a new way for SLE diagnosis.
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Background
Systemic lupus erythematosus (SLE) is the prototype of
complex autoimmune disease characterized by the pro-
duction of autoantibodies which results in widespread
immunologic abnormalities and immune complex for-
mation [1]. The patients can present variable manifesta-
tions and the nature courses are alternately remissions
and relapses. Till now, although a lot of related re-
searches have been undertaken [2], SLE patients have no
effective cures, whose treatments are often based upon
long-term broad-spectrum immune suppressive regimes
in the current therapeutic management. It becomes a
major public health problem.
The exact mechanism involved in SLE is needed to
understand. a lot of work has been done in searching for
biomarkers, from the aspects of DNA, mRNA and pro-
tein, expecting to illustrate the mechanism of SLE and
find ideal biomarkers for diagnosis and as a precaution
to SLE [3–5]. However, the underlying mechanism and
pathogenesis of SLE are still far away from understand-
ing. Novel methods should be looked into in this area.
As is known to all, the possibility of reprograming
somatic cells to induced pluripotent stem cells (iPSCs)
offers an opportunity to generate pluripotent patient-
specific cell lines, which can be beneficial for studying
pathogenesis of model human diseases [6]. Also, these
iPSCs lines are powerful tools for recapitulating disease
conditions and thus better understanding the underlying
mechanisms and pathogenesis of specific diseases [6].
iPSCs can be derived from immune cells as equally as
they can differentiate into specific immune cell types for
modeling diseases or clinical immunotherapy [6]. So far,
generations of iPSCs from urine, fibroblasts and kerati-
nocytes of disease patients have been reported [7, 8]. On
this basis, renal tubular cells-derived iPSCs were suc-
cessfully acquired from urine of SLE patients to study
SLE pathogenesis [9].
Currently, extensive researches, including those involv-
ing system-wide genomic and transcriptomic ap-
proaches, have been conducted to characterize iPSCs
[10]. However, molecular mechanisms remain insuffi-
ciently understood. At the molecular level, iPSCs are
more variable than embryonic stem cells (ESCs) [11]. It
is imperative that the compendium of differences de-
scribed between iPSCs and ESCs be considered as fur-
ther evidence for the fact that the reprogramming
process requires a wide variety of molecular changes. Be-
sides, cells can distinguish bona fide iPSCs from partial
reprogrammed cells during an earlier stage [11]. There-
fore, systematic deciphering of genetic or epigenetic al-
ternations would help to identify hotspots in iPSCs with
consistent genetic background [12].
Briefly, renal tubular cells–derived iPSCs were success-
fully obtained from urine of SLE patients and healthy
controls to understand the pathogenesis of SLE. For the
integration of multiple profiling datasets, simultaneous
expression profiling of microRNA, mRNA and protein
in SLE-iPSCs and NC-iPSCs were identified with Illu-
mina HiSeq™ 2000 System and iTRAQ-coupled 2D LC-
MS/MS analysis.
Results
mRNA, protein, miRNA expression profiles
In order to comprehensively reveal mRNA, microRNA
and protein interactions, we obtained high quality,
complete information and estimated the expression
levels of mRNA, miRNA and protein between the SLE-
iPSCs and control-iPSCs (Fig. 1).
For the mRNA expression profiling, P-value ≤ 0.05 and
FDR ≤ 0.001 were set as threshold value, 4,254 genes
were detected to have at least two-fold differences be-
tween SLE-iPSCs and control-iPSCs, The genes numbers
of 2,856 and 1,398 respectively represent the higher and
lower abundances of more than two fold compared with
control-iPSCs. Among 4,254 genes, 1,099 differentially
expressed ones built an interaction network, with 744
genes up-regulated and 355 down-regulated (Additional
file 1: Table S1).
Compared with the control group, it was found in the
microRNA libraries that 223 miRNAs were expressed at
the level of significant difference, with 126 up-regulated
miRNAs and 97 down-regulated ones in SLE-iPSCs
(Additional file 2: Table S2).
In the protein expression profiling, the identification
and quantification of 2,305 proteins in SLE-iPSCs and
control-iPSCs were performed with iTRAQ technique.
Given a confidence level of 95 %, 1.5-fold was set as
the cut-off criterion for up-regulated and down-
regulated proteins. Under these criteria, a total of 207
proteins were classified as differentially expressed
ones between SLE-iPSCs and control-iPSCs, with 55
showing increased abundance and the remaining 152
decreased abundance (Additional file 3, Additional file
4: Table S3,4).
MicroRNA-target genes regulation network
With integrated mRNA and microRNA transcriptome,
the expression change trend of miRNA target mRNAs
were focused on. Then, a systematically investigation
was conducted on the potential functional correlations
among microRNA target mRNAs. Cytoscape software
was used to construct the regulation network of differ-
entially expressed mRNAs. Their microRNA-target
mRNAs were predicted by using miRanda, TargetScan
and Pictar. If the target mRNAs were successfully pre-
dicted at least with two kinds of software at the same
time, they would be considered to be reliable.
MicroRNA-target mRNAs regulation network was
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shown in Figs. 2, 3. It can be seen that microRNA and
target genes were mutually cross-regulated.
A functional analysis was conducted based on Gene
Ontology. Some gene ontologies of biological processes,
molecular functions and cellular components were se-
lected, which were enriched by the features of the tran-
scriptomic and proteomic datasets with p value < 0.05.
In the study, GO enrichment analysis was performed
through functional annotation clustering of microRNA
and target genes, respectively. Totally, 11 biological pro-
cesses (BP), 4 molecular functions (MF) and 14 cellular
components (CC) GO terms were enriched in target
genes. 10 BP, 4 MF and 13 CC GO terms in microRNA
are shown in Fig. 4 a–b, respectively. BP includes trans-
lation, mRNA processing, nucleocytoplasmic transporta-
tion, vesicle-mediated transportation, cell motility and so
on. MF involves structural constituent of ribosome,
translation factor activity, nucleic acid binding, rRNA
binding, mRNA binding. CC contains nucleolus nucleus,
ribosome, Golgi apparatus, chromosome, endoplasmic
reticulum, cytoplasmic membrane-bounded vesicle,
mitochondrion, cytoplasmic membrane-bounded vesicle
and so on. According to the biological process, the
microRNA and target genes are mostly involved in BP
GO terms, structural constituent of ribosome of MF GO
term and nucleus of CC GO terms.
Generally, microRNAs are classified as a class of small
non-coding RNAs that bind complementary sequences
in target mRNAs to specifically regulate gene expression
through either mRNA degradation or translational in-
hibition [13]. If a target gene is down-regulated, it sug-
gests that effective activity of miRNA is enhanced under
the treatment, while an up-regulation of a target gene
indicates a decreased activity of the corresponding
Fig. 1 Data analysis overview. Stage 1: SLE-iPSCs and NC-iPSCs were used for the extraction of protein and RNA. Stage 2: Proteins were identified
with iTRAQ-coupled LC–MS/MS; the libraries of mRNA and miRNA were constructed by using the Illumina TruSeq RNA Sample Prep Kit v2-Set A
and TruSeq Small RNA Sample Prep Kit Set A, respectively, and then sequenced by using the Illumina HiSeq™ 2000 System. Stage 3: Protein dates
were submitted to the ProteinPilot analysis software for peptide identification and quantification, subsequently, differentially expressed proteins
were identified and quantified. Gene expressions based on sequencing were measured by RPKM values, ‘FDR(false discovery rate) ≤0.001 and the
absolute value of log2-Ratio ≥1’ as the threshold. Differentially expressed mRNAs and miRNAs were obtained. Stage 4: GO enrichment analysis
facilitated the mappings of all differentially expressed proteins, mRNAs and miRNAs to GO terms in the database (http: //www. geneontology.org/
). With PicTar, miRanda v5, TargetScan 5.1, differentially expressed target proteins and mRNAs were predicted. Stage 5: Differentially expressed
proteins and mRNAs were classified according to the GO database. With Cytoscape software,the regulation network of microRNA-target protein
and microRNA-target mRNA were analyzed. Stage 6: An integrated analysis of microRNA, target mRNAs and proteins was carried out using
Cytoscape software. Representative miRNA, mRNA and proteins were verified using Q-PCR and western blotting
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miRNAs. Consequently, a miRNA-mRNA interaction
pair means anti-regulation of a miRNA and a corre-
sponding mRNA [14, 15].
MicroRNA-target protein regulation network
In this study, a comparative proteome survey was
performed on the SLE-iPSC and control-iPSC using
iTRAQ technique. The identification and quantifica-
tion of differentially expressed proteins were realized.
In order to investigate the potential functional corre-
lations among microRNA target proteins, an inte-
grated systematic analysis was made on microRNA
and protein data. In addition, Cytoscape software
was applied to construct the regulation network of
microRNA and target protein. Given a 95 % confi-
dence level, the interaction network of 94 proteins
in 207 differentially expressed proteins were classi-
fied (Fig. 5); 37 MicroRNAs which regulated 49
target proteins were predicted. MicroRNA-target
proteins regulation network is shown in Fig. 5,
which manifests that microRNA- target protein were
mutually cross-regulated.
GO enrichment analyses of microRNA and target pro-
teins were performed, respectively. Totally, 4 BP, 3 MF
and 10 CC GO terms were enriched in target pro-
teins. 4 BP, 1MF and 9 CC GO terms in microRNA
are respectively shown in Fig. 6a–b. BP includes
translation, nucleocytoplasmic transport, embryo
development and mRNA processing; MF contains
structural constituents of ribosome; CC involves
nucleolusnucleus, ribosome, endoplasmic reticulum,
mitochondrion, cytoskeleton and so on. According to
biological process, the microRNA-target proteins are
mostly involved in the translation of BP GO terms,
structural constituent of ribosome of MF GO term
and nucleus of CC GO terms.
Fig. 2 MicroRNA-target network. Circles represent miRNA-target mRNAs, and triangles signify mRNA. The red nodes denote up-regulation, while
the blue nodes symbolize down-regulation. The lines stand for coherent miRNA -target genes interaction pairs
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mRNA-protein regulation network
For the purpose of identifying the correlations between
mRNA and protein expressions, the expression change
trend of transcriptomic and proteomic profiles were fo-
cused on. 1099 differentially expressed mRNAs and pro-
teins were found to be correlated in the mRNA-protein
library (Fig. 7).
A functional analysis was conducted through the
KEGG pathway. Given a cut-off criterion of Q-value <
0.05, 1109 differentially-expressed mRNAs were involved
in 235 pathways, and 99 differentially expressed proteins
in 65 pathways (Additional file 5, Additional file 6: Table
S5,6). According to the enrichment analysis, a few im-
portant pathways were significantly enriched in response
to SLE-iPSCs. It was quite evident that mRNAs and pro-
teins were both involved in ribosome, spliceosome, RNA
transport, lysine degradation and so on.
Based on the central dogma, it was generally as-
sumed that there was a direct correspondence be-
tween mRNA transcripts and generated protein
expressions. In recent years, various studies have
demonstrated the role of RNA-binding proteins
(RBPs) [16]. On the basis of mRNA-protein correl-
ation, it was found that 11 proteins and 11 mRNAs
were differentially expressed consistently (3 up-
regulated and 8 down-regulated, Fig. 8). To further
validate the expression data, 2 differentially expressed
mRNAs and proteins were randomly chosen and veri-
fied with Q-PCR and western blotting (Figs. 9, 10).
The common KEGG pathway of differentially
expressed proteins and mRNAs were analyzed using
GenMAPP v2.1. KEGG enrichment analyses showed that
proteins and mRNA significantly participated in ECM-
receptor interaction, fatty acid metabolism, ribosome,
spliceosome, RNA transport and so on(Additional file 5,
Additional file 6: Table S5,6).
mRNA-protein-microRNA regulation network
In order to integrate profiling datasets of differentially
expressed mRNAs, microRNAs and Proteins, the
mRNA-protein-microRNA regulation network was con-
structed with 39 down-regulated target proteins, 42
down-regulated mRNAs and 21 up-regulated miRNAs
(Fig. 11). The result indicated coherent miRNAs-target
proteins and miRNAs-target mRNAs interaction pairs.
This demonstrates that a single miRNA can target mul-
tiple proteins and mRNAs, while a single protein or
mRNA can be targeted by multiple miRNAs, which can
cooperatively repress a range of targets.
Discussion
After Takahashi and Yamanaka demonstrate that murine
fibroblasts can be reprogrammed into iPSCs in 2006
[17]. The application of powerful technique to humans
Fig. 3 microRNA-target mRNA sub-network. The mapping was constituted by 43 down-regulated target mRNAs and 21 up-regulated miRNAs. The
green circles represent down-regulated target mRNAs, and the red triangles denote up-regulated miRNAs. The lines stand for coherent miRNAs-target
mRNAs interaction pairs. A single miRNA can target multiple proteins, while a single protein can be targeted by several miRNAs. Multiple miRNAs can
cooperatively repress a range of targets
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opened the possibility to reprogram fibroblasts and/or
various specific immune cells isolated not only from
healthy people but also from patients suffering of a gen-
etic disease [6, 18]. What is more, the advances in stem
cell technology of iPSCs offer the opportunity to gener-
ate and directly analyze human autoimmune disease in
healthy and disease states [19]. Despite the fact that hu-
man iPSC-derived cells remained controversial to the
present day, the system has attested successful in vitro
replication of the main cellular characteristics already
known to be associated with the modeled disease [18].
Araki et al. [20] verified that no pronounced differences
in immunogenicity existed between the teratomas
formed by seven iPSCs and five embryonic stem cell
lines. Based on the research results, iPSCs can be de-
rived from syngeneic autologous cells as equally as they
can differentiate into specific immune cell types for
modeling diseases or clinical immunotherapy [6].
Network modeling, analysis and subsequent target
identification approach appear more promising in char-
acterizing diseases [21]. Biological networks comprise of
interactions between genes and proteins that co-ordinate
in the regulation of cellular processes [22]. Computa-
tional and systems biological techniques can be
employed to study the cellular level networks that medi-
ate physiological system dynamics [22]. In this study, an
Fig. 4 Gene ontology (GO) analysis. a GO analysis of differently expressed mRNA with p < 0.05, b GO analysis of differentially regulated target
mRNA. The horizontal axis indicates the names of the clusters in cellular component (CC), biological process (BP) and molecular function (MF),
respectively. The vertical axis displays the numbers of targets. The GO terms were sorted by the enrichment P-value, in an ascending order of
p-value from bottom to top
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integrative methodology was employed to combine the
data obtained through multiple expression profiling
methods, genomic sequence and bioinformatics analysis
of in-silico target miRNA, so as to investigate the im-
pacts of miRNA, mRNA and protein expression on SLE-
iPSCs.
Differentially expressed proteins, mRNAs and miRNAs
were systematically investigated. Computational methods
were adopted to predict miRNA interaction and
prioritize potential direct targets. Finally, mRNA-
proteomic mapping, miRNA-target mRNA network and
miRNA-target protein interactions were achieved. Sys-
tematic comparison results demonstrated the common
physiological changes in SLE-iPSCs and NC-iPSCs. Nu-
cleus and nucleolus in cellular component, transmem-
brane transport in biological process and structural
constituent of ribosome in molecular function were
found to be significant clustered in GO terms. That is to
say, systemic lupus erythematosus (SLE) is a systemic
non-organ specific autoimmune disease associated with
multiple autoantibodies targeting autoantigens from the
nucleus [23]. Anti-single and anti-double-stranded DNA
antibodies and rheumatoid factor were marker proteins
of SLE, which mainly derived from the cell nucleus. Our
results showed that differentially expressed proteins,
mRNAs and target miRNAs were mainly directed to nu-
clear constituents consistently. A subset of nuclear con-
stituents is directed to proteins and RNAs of the
ribosomes [24]. While a part of auto-antibodies directed
against some antigenic site composed of a portion of
both ribosomal RNA and ribosomal protein [25]. As a
result, differentially expressed proteins, mRNAs and tar-
get miRNAs, which are clustered in structural constitu-
ent of ribosome, will become markers of SLE in the
future.
Transport systems are essential to each living cell,
which is vital for all life-endowing processes, such as
communication, biosynthesis, reproduction, and co-
operative behaviors [26]. Given this, SLE is viewed as ex-
pressions of combined transport dysfunction syndromes
[27]. The results indicate that most differentially
expressed proteins, mRNAs and target miRNAs are clas-
sified as transmembrane transport in biological process.
In the light of the central dogma, it was generally as-
sumed that there was a direct correspondence between
mRNA transcripts and generated protein expressions. By
combining mRNA and protein expression data, it was
found that 11 proteins and 11 RNAs were differentially
Fig. 5 microRNA-target protein network. The mapping is composed of 48 differentially regulated target proteins and 36 differentially expressed
miRNAs. Green circles represent down- regulated target proteins, and red triangles signify up-regulated miRNAs. The lines stand for coherent
miRNAs-target proteins interaction pairs. A single miRNA can target multiple proteins, while a single protein can be targeted by several miRNAs.
Multiple miRNAs can cooperatively repress a range of targets
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expressed consistently in SLE-iPSCs and NC-iPSCs.
Transgelin (TAGLN), also known as smooth muscle
protein 22 (SM22), is a ubiquitous 22 kDa protein
among smooth muscle tissues of normal adult verte-
brates [28]. TAGLN plays a role in cell differentiation
by stabilizing the cytoskeleton through actin-binding
[29]. SM22/transgelin gene expression were down-
regulated during a variety of cell types [30, 31], as
well as in several human cancers, including lung,
renal and breast cancer [30, 32, 33]. TAGLN has been
proposed as a candidate tumor antigen [33]. The
study results showed that TAGLN was down-
regulated in SLE-iPSCs. Western blot and RT-PCR
confirmed the down-regulation of both TAGLN pro-
tein and mRNA. The former belongs to transcrip-
tional down-regulation. The mechanisms controlling
the regulations of other proteins require additional
study in SLE-iPSCs.
Adenylate kinase (AK) is an ATP-ADP phosphotrans-
ferase that catalyzes the interconversion of adenine nu-
cleotides, which are involved in maintaining the
homeostasis of adenine nucleotide composition in vari-
ous organisms [34]. AKs are proved to be multiple iso-
zymes, such as AK1, AK2, AK3 and AK4. These
isozymes are characterized by significantly conserved se-
quences and their sequences are fairly comparable [35].
The gene for human AK4 was identified in 1992 [36],
which is expressed mainly in tissues rich in mitochon-
dria like the brain, heart, kidney and liver [37]. Abnor-
mal expression of AK4 are proven in a variety of
diseases, such as Parkinson's disease [38], lung tu-
mors[39] and so on. Liu RJ et al. show that AK4 protein
Fig. 6 Gene ontology (GO) analysis. a GO analysis of differently expressed proteins with p < 0.05, b GO analysis of differentially regulated target
proteins. The horizontal axis indicates the names of the clusters in cellular component (CC), biological process (BP) and molecular function (MF),
respectively. The vertical axis displays the numbers of targets. The GO terms were sorted by the enrichment P-value, in an ascending order of
p-value from bottom to top
Tang et al. BMC Genomics  (2016) 17:488 Page 8 of 15
levels are increased in cultured cells exposed to hypoxia
and in an animal model of amyotrophic lateral sclerosis
(ALS), a neurodegenerative disease [40]. In our study,
AK4 protein and mRNA were found to be up-regulated
in SLE-iPSCs. Western blot and RT-PCR verified the up-
regulation of both AK4 protein and mRNA. It can be in-
ferred that AK4 is associated with the development of
SLE. However, its mechanism needs in-depth studies
with more detailed plans.
In biology process of cells, reproduction is controlled
not only by protein-coding genes but also by non-coding
regions, including loci that produce small RNAs [41].
MiRNAs, a family of small non-coding RNAs (typically
19–23 nucleotides) , have critical functions over a wide
range of biological and pathological processes [42], such
as translational repression, deadenylation, mRNA cleav-
age [43, 44]. MiRNAs are synthesized from short hairpin
precursors and that bind to complementary messenger
RNAs (mRNAs) to stimulate their degradation or re-
press their translation [41]. This complex circuitry of
miRNA–mRNA interactions has been studied massively
for over a decade in pursuit of identifying miRNA target
genes and evaluating the contribution of miRNAs to the
regulation of targeted genes [44]. Similarly, several stud-
ies have identified miRNA-protein interactions. Trabuc-
chi M et al. [45] show that RNA-binding protein
promotes the biogenesis of a subset of microRNAs.
Davis BN [46] report the smad proteins bind a con-
served RNA sequence to promote microRNA matur-
ation by Drosha. These studies indicate proteins that
directly bind different subsets of miRNA precursors and
enhance their processing by either Drosha, Dicer, or
both. Thus, one miRNA can target different mRNAs or
proteins, and one mRNA or protein can be under the
Fig. 7 Differentially expressed mRNA-Proteomic mapping. Differentially expressed mRNA- Proteomic regulation network was constructed.
Tetragons represent protein, and circles signify mRNA. The red nodes stand for up-regulation, and the blue nodes down-regulation. The red lines
denote experiment support, yellow lines interaction from PubMed, and blue lines interaction from database
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regulation of multiple miRNAs through a positive-
feedback loop [44], Dimitrios G et al. found that miR-
let-7 in conjunction with argonaute protein was found
to bind its own primary transcript to enhance its pro-
cessing by Drosha [47]. Our results indicated that miR-
371a-5p, conjunct with AK4 protein, was involved in
SLE.
The aim of presenting this report is to help predict
miRNA-RNA targets through the integrated analysis of
miRNA and mRNA expression profiling, as well as
miRNA protein targets using miRNA and protein regu-
lated network. The miRNA level of miR-371a-5p and
let-7a-5p were down-regulated in SLE-iPSC and verified
using Q-PCR. The up-regulation of AK4 involved in nu-
cleotide biosynthesis may suggest a general acceleration
of anabolic metabolism induced by down-regulated miR-
371a-5p, which may contribute to SLE. Recent studies
demonstrated that miR-371-5p was significantly elevated
in gastric cancer (GC) patients and regulated hepatocel-
lular carcinoma (HCC) cell proliferation, the miR-371-5
cluster has proved to be a novel prognostic factor and
therapeutic target for tumors and disease [48, 49]. Let-7a
is highly conserved among species in sequence and func-
tion [50], which operates as a tumor suppressor in hu-
man cells [51–53]. Serguienko A et al. [51] show that
let-7a down-regulates key anabolic enzymes and in-
creases both oxidative phosphorylation and glycolysis in
triple-negative breast cancer and metastatic melanoma
cell lines. Moreover, let-7a causes mitochondrial ROS
production concomitant with the up-regulation of
Fig. 9 Representative confirmations of relative gene expression in SLE-iPSCs and NC-iPSCs. a Representative TAGLN and AK4 were directly
detected through Western blotting using anti- TAGLN and AK4 antibodies, respectively. GAPDH was set as internal control with appropriate
antibodies. b, c Relative quantification of immunoblots. The vertical axes indicate the relative gray of TAGLN /GAPDH (B) and AK4/GAPDH c,
respectively. The horizontal axes display the groups of SLE-iPSCs and NC-iPSCs. Values of SD ±mean were plotted. Asterisk indicates the value
compared with that of control group with * P < 0.05
Fig. 8 A direct correspondence between mRNA transcripts and generated protein expressions was revealed
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Fig. 11 microRNA-target regulation network is composed of differentially expressed miRNAs, miRNA-target mRNAs and proteins. The mapping
was made up of 39 down-regulated target proteins, 42 down-regulated mRNAs and 21 up-regulated miRNAs. Green tetragons represent
down- regulated target proteins, green circles down-regulated target mRNAs, and red triangles up-regulated miRNA. The lines stand for coherent
miRNAs-target proteins and miRNAs-target mRNAs interaction pairs
Fig. 10 Relative mRNA and miRNA levels in SLE-iPSCs and NC-iPSCs. The mRNA levels of TAGLN a and AK4 b, as well as the miRNA level of let-
7a-5p c and miR-371a-5p d were used for Q-PCR experiments. The 18S rRNA level was set as the internal control of mRNA, and the U6 SnRNA
level as that of miRNA. The data were expressed as means ± SEM of three independent experiments. Asterisk indicates value compared with that
of control group with * P < 0.05
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oxidative stress responsive genes. Loss or down-
regulation of let-7 levels is associated with increased
cancer aggressiveness and poor clinical outcome [54].
This report also indicated that let-7a-5p was down-
regulated, which may be involved in SLE development.
Conclusion
In summary, a range of production SLE-iPSCs has been an-
alyzed to investigate the regulatory mechanism. In order to
integrate the biological system, global miRNA, mRNA and
proteomic expression profiling were employed in parallel.
1099 mRNAs, 223 microRNAs and 94 differentially
expressed proteins were verified. Computational and sys-
tems biological techniques can be employed to study the
regulated networks that mediate physiological system dy-
namics. To investigate the influence of miRNA on these
processes, potential targets of differentially expressed
mRNAs and Proteins were predicted using miRanda, Tar-
getScan and Pictar. Gene ontology (GO) analysis of differ-
entially expressed mRNAs and proteins found that
identified biological processes drive proliferation including
mRNA processing, translation and so on. Western blot and
RT-PCR confirmed the up-regulation of AK4 protein and
mRNA, as well as the down-regulation of TAGLN protein
and mRNA levels in SLE-iPSCs. MiR-371a- 5p and let-7a-
5p were down-regulated and verified using RT-PCR. The
up-regulation of AK4 involved in nucleotide biosynthesis
suggests a general acceleration of anabolic metabolism in-
duced by down-regulated miR-371a-5p, which may contrib-
ute to SLE. It is believed that the integration of multiple
profiling datasets will provide a useful tool for biologists
who are investigating biological networks and seeking to
identify direct regulators of mRNAs and proteins. It is also
expected that the knowledge gained from this study can as-
sess the usefulness of the pathogenesis and novel biomarker
candidates of SLE, which may develop a new way for diag-
nosis of SLE.
Methods
All studies and other procedures were approved by the
ethics committee of the Shenzhen People’s Hospital
(Shenzhen, China) or the Guangzhou Institutes of Bio-
medicine and Health (Guangzhou, China). 4 patients (four
women, mean age 39, range 30–46) were diagnosed as ac-
tive SLE with SLEDAI > 8. Patients treated with immuno-
suppressant within 3 months were excluded. Equivalent
subjects, age and sex matched, was recruited as healthy
controls. All participating subjects were explained their
participation rights. Written informed consent was ob-
tained. Renal tubular cells from urine of participating sub-
jects were reprogrammed to generate human iPSCs clone.
One SLE-iPSC clone and control-iPSC clone were identi-
fied [9], and which morphology were identified[9]. All of
the samples were collected and immediately frozen in li-
quid nitrogen and stored at −80 °C.
Sequencing of mRNA and miRNA
Total RNA was extracted from SLE-iPSCs and Control-
iPSCs using Trizol (Invitrogen, Carlsbad, USA) accord-
ing to the manufacturer's instructions. The concentra-
tion and quality of total RNA were measured by the UV
absorbance at 260 nm and 280 nm (A260/280) and
checked by gel electrophoresis. The polyA mRNAs were
selected by RNA Purification Beads (Illumina, SanDiego,
CA). MicroRNA isolation was carried out from the total
RNA using mirVana™ microRNA isolation kit (Ambion,
Austin, TX) according to the manufacturer's instruc-
tions. Total mRNA and miRNA isolated from three in-
dependent cultures were, respectively, pooled for
subsequent library construction and sequence analysis.
The libraries of mRNA and miRNA were constructed by
using the Illumina TruSeq RNA Sample Prep Kit v2-Set
A and TruSeq Small RNA Sample Prep Kit Set A, re-
spectively, sequenced by the Illumina HiSeq™ 2000 Sys-
tem. Adaptor sequences were subsequently trimmed to
clean full-length reads and formatted into a non-
redundant FASTQ format. The high-quality clean reads
were mapped to the reference human genome using the
SOAP (version 2.0) software. Sequences that perfectly
matched the genome along their entire length were con-
sidered for next analyses. Differential expression of
mRNA and miRNA between SLE-iPSCs and Control-
iPSCs were calculated by relative expression analysis.
Protein extraction, identification and relative
quantification
The process of protein extraction and iTRAQ sample
labeling were performed as described by our previous
research [55]. In briefly, the iPSC cells were harvested
and washed with ice-cold PBS, then lysed in ice-cold
lysis buffer. Protein concentration was determined by
Bradford Protein Assay Kit (Pierce). One hundred mi-
crograms of protein from each corresponding group
was digested with trypsin, and labeled according to
the iTRAQ protocol (Applied Biosystems). The la-
beled digests were subjected to liquid chromatography
coupled with tandem mass spectrometry (LC-MS/MS)
analysis. Once dates had been acquired, all data files
were processed by Mascot (version 2.3.02) and
searched against the IPI_human v3.87 database for
peptide identification and quantification, peptide
grouping into proteins and protein ratio calculation.
Only proteins with ≥ 1 peptides matched a ≥ 1 fold
difference in abundance in both directions and a p-
value < 0.05 were considered to be differentially
expressed protein.
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MicroRNA target predictions from differentially expressed
mRNA and differentially expressed protein
MiRNA target prediction was performed using three soft-
ware: PicTar: http://pictar.mdc-berlin.de/; miRanda v5:
http://www.ebi.ac.uk/enright%20srv/microcosm/htdocs/tar-
gets/v5/; TargetScan 6.2: http://www.targetscan.org/vert/.
When predicted at least by two software at the same time,
the result was considered reliable. Candidate miRNA-target
pairs were collected and further analyzed.
Data integration and analysis
The experiment, identified differentially expressed protein,
mRNA and miRNA, was combined with microRNA target
predictions to form integrated regulatory networks.
Namely, those data used as the input for differential ex-
pression identification and miRNA target prediction. Fi-
nally, acquired data were analyzed with the KEGGSOAP
software (http://www.bioconductor.org/packages/2.4/
bioc/html/KEGG SOAP.html). The results of regulatory
networks were handled in cytoscape software (http://
cytoscape. org).
Gene ontology
The predicted miRNA target mRNA, protein and the dif-
ferentially expressed mRNA, proteins were subjected to the
gene ontology analysis using KEGGSOAP software. The
target predictions and differentially expressed dates were
mapped to the GO annotation dataset, and the enriched
cellular component (CC), biological process (BP) and mo-
lecular function (MF) were extracted using the hypergeo-
metric test. a P < 0.05 was considered to be significant.
Western blotting
The SLE-iPSCs and NC-iPSCs were lysed with ice-
cold lysis buffer. Proteins were separated by SDS/
PAGE, electrophoresed, and transferred onto a PVDF
membrane. The membrane was incubated with pri-
mary antibodies to anti-TAGLN 1 : 500 (GeneTex) or
AK4 1 : 2000 (abcam) at 4 °C overnight, followed by
horseradish peroxidase (HRP)-conjugated goat anti-
rabbit immunoglobulin G (IgG) 1 : 2000 (southern
biotech) at room temperature for 2 h. The antibody-
bound proteins were analyzed by using immobilon
western chemilum HRP substrate (Millipore). The
quantitative analysis of the immunoblot results were
performed using Image J software.
Q-PCR analysis
Total RNA of SLE-iPSCs and NC-iPSCs was extracted
with trizol (Invitrogen) and reversed to cDNA using
iScript™ cDNA Synthesis Kit (Bio-Rad). The following
specific primers were used: TAGLN, forward: 5’-
ATGGCGTGATTCTGAGCAA-3’, reverse: 5’-ATCTG
CTTGAAGACCATGG A-3’; AK4, forward: 5’-GCCC
AGGCTAATCTATGAAG-3’, reverse: 5’-CAAGGAGCT-
CAAAAG CCTAT-3’; 18 s rRNA, forward: 5’-CCTGGA-
TACCGCAGCTAGGA-3’, reverse: 5’-GCGGCGCAATA
CGAATGCC CC-3’; miR-371a-5p, forward: 5’-ACA
CTCCAGCTGGGTAGCTTATCAGACTGAT G-3’; let-
7a-5p, forward: 5’-ACA CTCCAGCTGGGACTCAAA
CTGTGGGGGC-3’, miRNA, reverse: 5’-CTCAACT
GGTGTCGTGGA-3’; U6, forward: 5’-CTCGCTTCGGC
AGCACA-3’, reverse: 5’-AA CGCTTCACG AATTT
GCGT-3’. Q-PCR was performed on a Real-time PCR
system (Bio-Rad) using individual PCR tubes (Bio-Rad).
The relative expression level was calculated from a rela-
tive standard curve obtained by using log dilutions of
cDNA containing genes of TAGLN, AK4, miR-371a-5p,
let-7a-5p. The relative expression was quantified using
the “2-ΔΔCt” method [56]. The average of three inde-
pendent analyses for each gene was calculated.
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